Is initial combination therapy effective in the treatment of type 2 diabetes?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 5, 2006, Pages 254-255

  Riddle, Matthew C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE;

ADULT; AGED; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MAXIMUM PERMISSIBLE DOSE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 33646593807     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0167     Document Type: Note

References (5)

1. Riddle MC (2005) Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 34: 77-98
2. Riddle M (2000) Combining sulfonylureas and other oral agents. Am J Med 108 (Suppl 6A): 15S-22S
3. Zammitt NN et al. (2005) Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28: 2948-2961
4. UK Prospective Diabetes Study (UKPDS) Group (1995) UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-1258
5. Hanefeld M et al. (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27: 141-147